April 20, 2021 -- Code Biotherapeutics has launched with $10 million in financing and will focus on next-generation nonviral gene therapies.
The Philadelphia-based company has developed a proprietary synthetic DNA-based vector called 3DNA that has the potential to deliver genes of all sizes to multiple cell types as a redosable therapy for the treatment of many genetic disorders. Code is developing a pipeline of novel gene therapies to treat rare genetic diseases such as Duchenne muscular dystrophy and type 1 diabetes. The company is also actively seeking partnerships in other strategic areas.
The seed financing was co-led by 4BIO Capital and UPMC Enterprises, with participation from CureDuchenne Ventures, JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures.
Copyright © 2021 scienceboard.net